Ilyang PharmaceuticalLtd Past Earnings Performance
Past criteria checks 0/6
Ilyang PharmaceuticalLtd's earnings have been declining at an average annual rate of -12%, while the Pharmaceuticals industry saw earnings growing at 7.8% annually. Revenues have been growing at an average rate of 3.1% per year.
Key information
-12.0%
Earnings growth rate
-12.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 3.1% |
| Return on equity | 0.8% |
| Net Margin | -0.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Ilyang PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 364,562 | -738 | 141,400 | 29,615 |
| 30 Jun 24 | 366,053 | 642 | 140,394 | 26,988 |
| 31 Mar 24 | 368,707 | -3,358 | 144,064 | 27,959 |
| 31 Dec 23 | 370,537 | -2,467 | 142,888 | 27,439 |
| 30 Sep 23 | 367,432 | 5,506 | 143,930 | 28,106 |
| 30 Jun 23 | 380,654 | 8,435 | 145,825 | 28,451 |
| 31 Mar 23 | 378,437 | 15,678 | 143,612 | 26,792 |
| 31 Dec 22 | 383,811 | 18,789 | 146,357 | 25,960 |
| 30 Sep 22 | 389,454 | 21,260 | 146,517 | 24,736 |
| 30 Jun 22 | 376,539 | 21,234 | 143,243 | 22,402 |
| 31 Mar 22 | 374,957 | 20,009 | 140,801 | 22,009 |
| 31 Dec 21 | 371,348 | 14,384 | 140,496 | 20,196 |
| 30 Sep 21 | 351,562 | 11,559 | 135,128 | 18,647 |
| 30 Jun 21 | 353,265 | 8,727 | 130,360 | 18,822 |
| 31 Mar 21 | 353,771 | 8,045 | 130,575 | 18,719 |
| 31 Dec 20 | 343,329 | 10,880 | 124,820 | 19,723 |
| 30 Sep 20 | 336,954 | 10,558 | 123,825 | 19,832 |
| 30 Jun 20 | 324,142 | 9,487 | 125,151 | 18,064 |
| 31 Mar 20 | 319,242 | 8,493 | 123,360 | 18,555 |
| 31 Dec 19 | 324,573 | 9,985 | 127,632 | 15,850 |
| 30 Sep 19 | 323,111 | 703 | 127,264 | 14,046 |
| 30 Jun 19 | 311,322 | -5,138 | 125,178 | 15,086 |
| 31 Mar 19 | 304,435 | -4,821 | 123,568 | 12,168 |
| 31 Dec 18 | 300,036 | -4,893 | 121,682 | 12,844 |
| 30 Sep 18 | 289,460 | 6,970 | 113,271 | 15,045 |
| 30 Jun 18 | 291,974 | 8,474 | 109,429 | 13,408 |
| 31 Mar 18 | 282,462 | 9,139 | 103,595 | 12,889 |
| 31 Dec 17 | 269,811 | 6,265 | 97,244 | 12,387 |
| 30 Sep 17 | 262,214 | 4,475 | 97,153 | 11,098 |
| 30 Jun 17 | 262,323 | 6,101 | 93,628 | 10,686 |
| 31 Mar 17 | 263,159 | 5,206 | 90,957 | 10,937 |
| 31 Dec 16 | 261,615 | 5,848 | 87,969 | 10,806 |
| 31 Dec 15 | 239,263 | 4,409 | 75,694 | 14,390 |
| 30 Sep 15 | 237,556 | -2,266 | 78,189 | 8,671 |
| 30 Jun 15 | 226,844 | -4,442 | 77,475 | 8,850 |
| 31 Mar 15 | 211,798 | -10,962 | 76,060 | 8,361 |
| 31 Dec 14 | 195,872 | -9,193 | 67,842 | 10,669 |
| 30 Sep 14 | 179,412 | -5,320 | 59,085 | 10,972 |
| 30 Jun 14 | 158,829 | -530 | 52,147 | 8,832 |
| 31 Mar 14 | 147,732 | 3,963 | 46,087 | 7,424 |
Quality Earnings: A007575 is currently unprofitable.
Growing Profit Margin: A007575 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A007575 is unprofitable, and losses have increased over the past 5 years at a rate of 12% per year.
Accelerating Growth: Unable to compare A007575's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A007575 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).
Return on Equity
High ROE: A007575 has a negative Return on Equity (0.8%), as it is currently unprofitable.